Key result
XGBoost high-risk classification linked to a ~10-fold increase in 3-year all-cause mortality.
Why the study?
Accurate individual risk prediction for 3-year mortality in patients with cardiovascular-kidney-metabolic syndrome remains limited.
Does an 8-variable XGBoost machine learning model accurately predict 3-year all-cause mortality in hospitalized patients with CKM stages 2-4?
Cohort (n=219,561)
Yes
Does an 8-variable XGBoost machine learning model accurately predict 3-year all-cause mortality in hospitalized patients with CKM stages 2-4?
Hazard Ratio: 9.62 (95% CI 8.86–10.45)
Absolute Event Rate: 254.7% vs 5.9%
p-value: p=<0.001
An 8-variable XGBoost machine learning model provides accurate, validated 3-year mortality risk stratification for hospitalized patients with CKM syndrome stages 2-4.
May aid CKM mortality risk stratification; leaves open prospective validation before clinical use.
Cardiovascular-kidney-metabolic (CKM) syndrome is associated with a high risk of mortality, yet accurate individual risk prediction remains limited. We developed and validated machine learning models to predict 3-year all-cause mortality in 219,561 hospitalized patients with CKM stages 2-4 from 29 medical centers. Extreme Gradient Boosting (XGBoost) and least absolute shrinkage and selection operator (LASSO) models were developed in a derivation cohort ( n = 132,404) using 101 variables and evaluated in internal ( n = 56,744) and center-based ( n = 30,413) validation cohorts. An 8-variable XGBoost model consistently outperformed the LASSO model, achieving receiver operating characteristic curve [ROC-AUC] of 0.831, 0.826, and 0.813 in the derivation, internal, and center-based validation cohorts, respectively. Based on the optimal model, patients were stratified into low-, moderate-, and high-risk groups. Compared with the low-risk group, high-risk patients had substantially higher risks of 3-year all-cause mortality (hazard ratio [HR], 9.62 [8.86, 10.45]) and cardiovascular mortality (HR, 12.53 [10.97, 14.31]). A web-based risk calculator was developed to facilitate clinical application. This parsimonious 8-variable XGBoost model provides accurate mortality risk stratification and may support personalized management of patients with CKM syndrome.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) conducted a cohort in Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 2-4 (n=219,561). High-risk classification by XGBoost model vs. Low-risk classification was evaluated on 3-year all-cause mortality (HR 9.62, 95% CI 8.86-10.45, p=<0.001). Patients classified as high-risk by an 8-variable XGBoost model had a substantially higher risk of 3-year all-cause mortality compared to low-risk patients (HR 9.62).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: